Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: An alpe adria thoracic oncology multidisciplinary group study (ATOM 014)

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1354-1360

  Grossi, Francesco ^a   Spizzo, Riccardo ^b   Bordo, Domenico ^a   Cacitti, Veronica ^c   Valent, Francesca ^c   Rossetto, Ciro ^c   Follador, Alessandro ^c   Di Terlizzi, Silvia ^c   Aita, Marianna ^c   Morelli, Angelo ^c   Fasola, Gianpiero ^c   Consiglieri, Clara ^a   Ceschia, Tino ^c   Beltrami, Carlo A ^c   Belvedere, Ornella ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Prognostic markers; Stage IIIA NSCLC; Tissue microarrays; Unsupervised hierarchical clustering analysis

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; MOLECULAR MARKER; PROTEIN BCL 2; STEM CELL FACTOR RECEPTOR; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

EID: 77956262655     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e77a78     Document Type: Article

References (28)

1. Robinson LA, Ruckdeschel JC, Wagner H, et al. Treatment of non-small cell lung cancer\stage IIIA. ACCP Evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:243S-265S.
2. Rigas JR, Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007;2(Suppl 2):S77-S85.
3. Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:603-612.
4. Lee JG, Lee CY, Bae MK, et al. Validity of International Association for the Study of Lung Cancer Proposals for the revision of N descriptors in lung cancer. J Thorac Oncol 2008;3:1421-1426.
5. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
6. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarray progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008;26:5630-5637.
7. Scagliotti GV. Potential role of multitargeted tyrosine kinase inhibitors in non-small-cell lung cancer. Ann Oncol 2007;18:S32-S41.
8. Bunn PA, Shepherd FA, Sandler A, et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003;41:S175-S186.
9. Harari PM, Allen GW, Bonner JA. Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol 2007;25:4057-4065.
10. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007;14:942-953.
11. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-193.
12. Blagden S, de Bono J. Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 2005;6:325-335.
13. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Car-diovasc Surg 1978;76:832-839.
14. Sobin LH, Wittekind CH. (Eds.) TNM Classification of Malignant Tumours, 5th Ed. New York: Wiley-Liss, 1997.
15. Travis WD, Colby TV, Corrin B, et al. (Eds.) In Collaboration with Sobin LH and Pathologists from 14 Countries. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. 3rd Ed. Geneva, IL: Springer-Verlag, 1999.
16. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95: 14863-14868.
17. Chiang DY, Brown PO, Eisen MB. Visualizing associations between genome sequences and gene expression data using genome-mean expression profiles. Bioinformatics 2001;17:S49-S55.
18. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;11:3974-3986.
19. Vielh P, Spano JP, Grenier J, et al. Molecular prognostic factors in resectable non-small cell lung cancer. Crit Rev Oncol Hematol 2005;53: 193-197.
20. Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small-cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.
21. Knudsen KE, Diehl JA, Haiman CA, et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006;25:1620-1628.
22. Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55:1-14.
23. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected in non-small cell lung cancer. Clin Cancer Res 1997;3:1051-1058.
24. Anton RC, Coffey DM, Gondo MM, et al. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Mod Pathol 2000;13:1167-1172.
25. Gugger M, Kappeler A, Vonlanthen S, et al. Alterations of cell cycle regulators are less frequent in advanced non small cell lung cancer than in resectable tumours. Lung Cancer 2001;33:229-239.
26. Betticher DC, Thatcher N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-1011.
27. Li R, An SJ, Chen ZH, et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Hum Pathol 2008;39:1792-1801.
28. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohisto-chemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101-109.